Description
Background: In 2012 the U.S. Food and Drug Administration (FDA) approved the drug emtricitabine/tenofovir for use as Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP) after proving to be safe and effective at preventing HIV in multiple peer-reviewed studies. Despite the proven safety and value of PrEP treatment, use remains low in practice.
Download count: 0
Details
Contributors
- Schlumbrecht, Benjamin (Author)
- Link, Denise (Thesis advisor)
Date Created
The date the item was original created (prior to any relationship with the ASU Digital Repositories.)
2018-04-18
Resource Type
Collections this item is in
Collaborating institutions